#ES­MO22: Bris­tol My­ers spells out kid­ney can­cer flop for Op­di­vo/Yer­voy com­bo — but can a triplet catch on?

Bris­tol My­ers Squibb is com­ing to #ES­MO22 with mixed da­ta on its Op­di­vo/Yer­voy com­bo — a dual im­munother­a­py strat­e­gy that it’s been try­ing to push for years — in kid­ney can­cer.

While Bris­tol My­ers’ own Phase III study failed the pri­ma­ry end­point of dis­ease-free sur­vival, Ex­elix­is is show­cas­ing Phase III da­ta where a com­bi­na­tion of Cabome­tyx with Op­di­vo and Yer­voy im­proved pro­gres­sion-free sur­vival over the PD-1/CT­LA-4 com­bo alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER